Revenue
No reported data
Rapport Therapeutics, Inc. (RAPP)
Price—Loading quote
Net income
2023
2024
2025
Free cash flow
2023
2024
2025
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Research & development | $94.8M | $60.9M | $28.0M |
| Operating expenses | $125.1M | $83.1M | $36.2M |
| Operating income | −$125.1M | −$83.1M | −$36.2M |
| EBITDAderived | −$124.1M | −$82.2M | −$36.1M |
| Net income | −$111.5M | −$78.3M | −$34.8M |
| Basic EPSper diluted share | -$2.86 | -$3.78 | -$23.10 |
| Diluted EPSper diluted share | -$2.86 | -$3.78 | -$23.10 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 26, 2026Form 4 · 10b5-1 | Third Rock Ventures V, L.P. +5TenPercentOwner | SellCommon Stock | 18.6K | $40.05 | $743.8K | 6.28M |
| May 11, 2026Form 4 · 10b5-1 | Third Rock Ventures V, L.P. +5TenPercentOwner | SellCommon Stock | 133.6K | $40.24 | $5.38M | 6.30M |
| May 8, 2026Form 4 · 10b5-1 | Third Rock Ventures VI, L.P. +5TenPercentOwner | SellCommon Stock | 5.0K | $40.31 | $202.3K | 6.43M |
| May 7, 2026Form 4 · 10b5-1 | Third Rock Ventures VI, L.P. +5TenPercentOwner | SellCommon Stock | 271.5K | $40.12 | $10.89M | 6.44M |
| Apr 17, 2026Form 4 · 10b5-1 | Third Rock Ventures VI, L.P. +5TenPercentOwner | SellCommon Stock | 426.0K | $40.32 | $17.18M | 6.71M |